MESO
Mesoblast Limited · Healthcare
14.87
0.41%(+0.06)
Prev. Close18.00
21.05%(+3.13)
Pre-marketLast Updated: — ET
52W L: $9.6652W H: $21.50
$14.10
CHG-1.25 (-8.14%)
H$16.33
L$14.02
VOL3.9M
MESO (1h)
Mesoblast Limited · Healthcare
Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net sales were US$30.3 million for the quarter ended March 31, 2026.1 Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first year of Ryoncil® launch approaches US$100 million.
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast's senior leadership team and from key opinion leaders.
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs in new pediatric and adult inflammatory conditions in partnership with investigators and key opinion leaders.
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical
Mesoblast Limited (NASDAQ: MESO - Get Free Report)'s stock price gapped down before the market opened on Friday. The stock had previously closed at $16.92, but opened at $15.80. Mesoblast shares last traded at $15.87, with a volume of 179,801 shares. Wall Street Analyst Weigh In Separately, Weiss Ratings reiterated a "sell (e+)" rating on
Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
BURNS WILLIAM MURRAY
director
0 SH @ $0.00
2026-03-18
BURNS WILLIAM MURRAY
director
33,334 SH @ $1.81
2022-11-17
BURNS WILLIAM MURRAY
director
136,550 SH @ $0.36
2024-10-12
BURNS WILLIAM MURRAY
director
50,000 SH @ $0.97
2025-08-27
Itescu Silviu
director, officer: CEO and Managing Director
0 SH @ $0.00
2026-03-18
Itescu Silviu
director, officer: CEO and Managing Director
0 SH @ $0.00
2026-03-18
Itescu Silviu
director, officer: CEO and Managing Director
0 SH @ $0.00
2026-03-18
Itescu Silviu
director, officer: CEO and Managing Director
673,333 SH @ $1.45
2026-03-18